PCVX - CIK 0001649094
The table below shows Vaxcyte, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $260.84M | $281.08M | $306.74M | $346.85M | $1.05B | $518.67M |
| Short-term investments | $1.48B | $1.43B | $1.35B | $1.32B | $1.13B | $934.03M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.81B |
| $1.77B |
| $1.72B |
| $1.72B |
| $2.21B |
| $1.48B |
| Property, plant & equipment | $260.69M | $253.49M | $242.27M | $217.16M | $163.24M | $125.97M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $3.35B | $3.17B | $3.31B | $3.38B | $3.56B | $2.09B |
| Accounts payable | $63.06M | $48.96M | $31.41M | $20.51M | $18.22M | $10.47M |
| Total current liabilities | $242.08M | $200.05M | $154.49M | $97.00M | $123.79M | $82.85M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $352.29M | $278.72M | $234.03M | $178.08M | $142.11M | $101.14M |
| Retained earnings | -$2.48B | -$1.91B | -$1.70B | -$1.53B | -$1.25B | -$1.15B |
| Total equity | $3.00B | $2.89B | $3.07B | $3.20B | $3.42B | $1.99B |